Loading provider…
Loading provider…
Hematology & Oncology Physician in Louisville, KY
NPI: 1164440962Primary Practice Location
SCHNECK MEDICAL CENTER
411 W Tipton St, Seymour, IN
Primary Employer
Veterans Administration Medical Center
va.gov
HQ Phone
Get MD Naveed's Phone NumberMobile
Get MD Naveed's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 636 | 2,377 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 432 | 695 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 269 | 317 |
| 4 | 80053Blood test, comprehensive group of blood chemicals | 161 | 619 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 152 | 874 |
Authors: Nathan Pennell, Heather Wakelee, Primo Lara, John Choe, Shirish Gadgeel, Thomas Lynch
Journal: J Thorac Oncol
Authors: David Berz, Mohammad Jahanzeb, Ajit Maniam, Lyudmila Bazhenova, Petros Nikolinakos, David Camidge, Nehal Masood
Journal: J Thorac Oncol
Publication Date: 2020-09-09
Lead Sponsor: Sermonix Pharmaceuticals Inc.
Collaborators: Linical Accelovance Group
Intervention / Treatment: DRUG: Fulvestrant, DRUG: Lasofoxifene
Lead Sponsor: Novartis Pharmaceuticals
Collaborators: Translational Research in Oncology
Intervention / Treatment: DRUG: Ribociclib, OTHER: Endocrine Therapy
Lead Sponsor: Pfizer
Collaborators: Merck KGaA, Darmstadt, Germany, Ono Pharmaceutical Co. Ltd, Pierre Fabre Medicament
Intervention / Treatment: DRUG: Cetuximab, DRUG: Irinotecan, DRUG: Encorafenib, DRUG: 5-Fluorouracil, DRUG: Folinic Acid, DRUG: Binimetinib